Active substances
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NUEDEXTA | 20MG;10MG | capsule · oral | OTSUKA AMERICA PHARM | Prescription | 29 Oct 2010 |
| DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE | 20MG;10MG | capsule · oral | ACTAVIS ELIZABETH | Prescription | 10 Oct 2017 |
| DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE | 20MG;10MG | capsule · oral | HETERO LABS LTD III | Prescription | 28 Aug 2024 |
| DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE | 20MG;10MG | capsule · oral | SUN PHARM | Prescription | 3 Jun 2026 |
Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NUEDEXTA 20-10 MG CAPSULE | $26.63535 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.